samedan logo
 
 
 
spacer
home > ebr > summer 2021 > accelerating ov immunotherapeutic innovation to market
PUBLICATIONS
European Biopharmaceutical Review

Accelerating OV Immunotherapeutic Innovation to Market

Leveraging the process and analytical expertise of specialised external CDMO partners early in development of oncolytic viruses (OVs) has become a beneficial strategy in providing additional capabilities and insights for many biotech companies approaching this type of cancer treatment.

What science and capabilities are key to creating OVs with safe, efficacious, and robust processes to produce OV programmes? Why it is critical to find specialised commercial partners, and how is best to engage them in the dynamic sector of oncological immunotherapeutic science?

Global spending on cancer therapies and supportive care drugs is expected to reach $200 billion by 2022 (1). With an estimated 18 million cancer cases around the world in 2018, cancer is a leading cause of death and has become an enormous social burden (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Before Vibalogics, Kai Lipinski PhD served as Principal Scientist at Cobra Biologics, focusing on upstream process development for virus and mammalian protein expression projects. Prior to that, Kai worked as Senior Principal Scientist at ML Laboratories, where he was responsible for the development of targeted adenoviral vectors for cancer gene therapy approaches. As Chief Scientific Officer at Vibalogics, Kai is central to the establishment of virus process development and manufacturing capabilities, technical developments, and the acquisition of many key clients.

Kai has a PhD in Transcriptional Regulation by Adenoviral E1A Proteins, and a Post-Doctorate, also on Transcriptional Regulation, from the University of Duisburg-Essen, Germany
spacer
Kai Lipinski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement